Michigan Nanotechnology Institute for Medicine and Biological Sciences, Department of Internal Medicine, Graduate Program in Immunology, University of Michigan, School of Medicine, 109 Zina Pitcher Place, BSRB, Room 4039, Ann Arbor, MI 48109, USA.
Expert Rev Vaccines. 2012 Jul;11(7):787-90. doi: 10.1586/erv.12.46.
In the study under evaluation, optimized SIV DNA were used to boost T-cell responses induced by a highly immunogenic SIV Ad5-prime in Chinese rhesus macaques. A regular prime-boost regimen (SIV DNA-prime and rAd boost) and naive macaques were used as the control. After vaccination, the animals were challenged intrarectally with SIVmac251, and partial protection was observed in the macaques immunized by the Ad5-prime DNA-boost regimen. SIV-specific T-cell responses in the enzyme-linked immunospot assay were significantly higher in the Ad5-prime DNA-boost, compared with the responses in the control macaques. Viral control correlated with the generation of HLA-DR+ T cells 2 weeks after the viral challenge. Further studies using prime and boost strategies and alternative routes of vaccination (including a simultaneous approach) are warranted to fully explore the potential of prime and boost regimens for HIV-1 vaccine development.
在本评估研究中，使用优化的 SIV DNA 来增强中国恒河猴中高度免疫原性的 SIV Ad5-prime 诱导的 T 细胞反应。使用常规的初免-加强免疫方案（SIV DNA-prime 和 rAd boost）和未经免疫的恒河猴作为对照。接种疫苗后，动物通过直肠内接种 SIVmac251 进行攻毒，在 Ad5-prime DNA-boost 免疫的恒河猴中观察到部分保护。与对照恒河猴相比，在酶联免疫斑点分析中，Ad5-prime DNA-boost 免疫的恒河猴中 SIV 特异性 T 细胞反应显著更高。病毒控制与病毒攻击后 2 周 HLA-DR+ T 细胞的产生相关。需要进一步使用初免-加强免疫策略和替代的疫苗接种途径（包括同时接种）进行研究，以充分探索初免-加强免疫方案在 HIV-1 疫苗开发中的潜力。
